Sonoma Pharmaceuticals (NASDAQ:SNOA) Issues Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings results on Wednesday. The company reported ($0.59) earnings per share for the quarter, Zacks reports. Sonoma Pharmaceuticals had a negative return on equity of 59.58% and a negative net margin of 27.21%.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA traded down $0.03 during mid-day trading on Wednesday, reaching $2.66. 17,300 shares of the company’s stock traded hands, compared to its average volume of 56,988. The stock has a market cap of $3.56 million, a P/E ratio of -0.53 and a beta of 1.43. Sonoma Pharmaceuticals has a 12 month low of $2.44 and a 12 month high of $9.37. The stock’s 50-day moving average is $2.69 and its two-hundred day moving average is $2.36.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.